MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 100626 | Name: Mitobronitol
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mitobronitol (1,6-dibromo-1,6-dideoxy-D-mannitol) is a brominated analog of mannitol. It is an anticancer drug that is classified as an alkylating agent. (Source: http://en.wikipedia.org/wiki/Mitobronitol)

Chemical Structure

Mitobronitol
Mitobronitol
CAS#488-41-5

Theoretical Analysis

MedKoo Cat#: 100626

Name: Mitobronitol

CAS#: 488-41-5

Chemical Formula: C6H12Br2O4

Exact Mass: 305.9102

Molecular Weight: 307.96

Elemental Analysis: C, 23.40; H, 3.93; Br, 51.89; O, 20.78

Price and Availability

Size Price Availability Quantity
100mg USD 350.00 2 weeks
250mg USD 650.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
16dibromo16dideoxyDMannitol
IUPAC/Chemical Name
(2S,3S,4S,5S)-1,6-dibromohexane-2,3,4,5-tetraol
InChi Key
VFKZTMPDYBFSTM-KVTDHHQDSA-N
InChi Code
InChI=1S/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4-,5-,6-/m1/s1
SMILES Code
O[C@@H]([C@@H](O)[C@H](O)[C@H](O)CBr)CBr
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Mitobronitol (1,6-dibromo-1,6-dideoxy-D-mannitol) is a brominated analog of mannitol. It is an anticancer drug that is classified as an alkylating agent. Pharmacological action: antineoplastic agent, alkylating.       

Preparing Stock Solutions

The following data is based on the product molecular weight 307.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tanaka Y, Nagai Y, Mori M, Fujita H, Togami K, Kurata M, Matsushita A, Maeda A, Nagai K, Tanaka K, Takahashi T. Multiple granulocytic sarcomas in essential thrombocythemia. Int J Hematol. 2006 Dec;84(5):413-6. PubMed PMID: 17189221. 2: Barta A, Dénes R, Masszi T, Reményi P, Bátai A, Torbágyi E, Sipos A, Lengyel L, Jakab K, Gyódi E, Réti M, Földi J, Páldi-Haris P, Avalos M, Pálóczi K, Fekete S, Török J, Hoffer I, Jakab J, Váradi G, Kelemen E, Petrányi G. Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. Acta Haematol. 2001;105(2):64-70. PubMed PMID: 11408706. 3: Windrum P, Hull DR, Morris TC. Herb-drug interactions. Lancet. 2000 Mar 18;355(9208):1019-20. PubMed PMID: 10768466. 4: Barta A, Bátai A, Kelemen E, Lengyel L, Reményi P, Sipos A, Torbágyi E, Avalos M, Fekete E, Földi J, Páldi-Haris P, Tamáska J, Gyódi E, Rajczy K, Hoffer I, Jakab J, Petrányi GG, Pálóczi K. Immunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state. Hum Immunol. 2000 Feb;61(2):101-10. Review. PubMed PMID: 10717801. 5: Masszi T, Reményi P, Kriván G, Goda V, Réti M. Allogeneic bone marrow transplantation for acute leukemia in adults. Bone Marrow Transplant. 1998 Dec;22 Suppl 4:S77-9. PubMed PMID: 9916643. 6: Barta A, Batai A, Torbagyi E, Sipos A, Lengyel L, Petranyi GG, Paloczi K, Kelemen E. Haemopoietic cell transplantation activity and results: a single institution experience. Bone Marrow Transplant. 1998 Dec;22 Suppl 4:S60-2. PubMed PMID: 9916638. 7: Kelemen E, Dénes R, Barta A, Masszi T, Reményi P, Pálóczi K, Bátai A, Torbágyo E, Sipos A, Lengyel L, Jakab K, Gyódi E, Réti M, Földi J, Páldi-Haris P, Manuel A, Fekete S, Török J, Hoffer I, Jakab J, Váradi G, Petrányi G. [A new radiation-free conditioning in bone marrow transplantation and dibromo-mannitol therapy in chronic myeloid leukemia]. Orv Hetil. 1998 Aug 23;139(34):2003-1; discussion 2011-2. Review. Hungarian. PubMed PMID: 9745304. 8: Kelemen E, Masszi T, Reményi P, Barta A, Pálóczi K. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination. Bone Marrow Transplant. 1998 Apr;21(8):747-9. PubMed PMID: 9603396. 9: Szebeni J, Barna K, Uher F, Milosevits J, Pálóczi K, Gaál D, Petrányi GG, Kelemen E. Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning. Leukemia. 1997 Oct;11(10):1769-74. PubMed PMID: 9324299. 10: Tsuji T. Erythemas associated with essential thrombocythemia. J Dermatol. 1995 Oct;22(10):788-94. PubMed PMID: 8586763.